Isofol's CEO Ulf Jungnelius has subscribed for all warrants
GOTHENBURG, Sweden, August 4, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL), today announced that the CEO Ulf Jungnelius has chosen to make full use of the opportunity to subscribe for all warrants in the incentive program for the CEO – The Warrant Program 2020.The program, which was decided at the Annual General Meeting on June 24, 2020, has been designed as a supplementary program only aimed at the company's CEO who did not participate in Warrant Program “2018”. The program, which includes a maximum of 250,000 warrants, will